Literature DB >> 18682983

Plasma endothelin-1 and nitrate levels in Down's syndrome with complete atrioventricular septal defect-associated pulmonary hypertension: a comparison with non-Down's syndrome children.

Metin Sungur1, Burhan Ocal, Deniz Oğuz, Selmin Karademir, Cemşit Karakurt, Filiz Senocak.   

Abstract

Children with Down's syndrome (DS)-associated complete atrioventricular septal defect (AVSD) have rapid and aggressive development of pulmonary vascular disease when compared with non-Down's syndrome (ND) children. We aimed to evaluate the role of plasma endothelin-1 (ET-1) and nitrate levels in DS children with complete AVSD-associated pulmonary hypertension (PH) and compare this to ND patients. The study included 20 patients (11 males, nine females) who had complete AVSD associated with PH. Comparisons were made between DS patients (n=12) aged 4 to 8 months (median 5 months) and ND patients (n=8) aged 4 to 12 months (median 7 months). Blood samples were drawn from the inferior vena cava, pulmonary artery, pulmonary vein, and aorta. The plasma ET-1 concentrations of the two groups were compared to the peripheral venous and arterial ET-1 levels, and pulmonary vein nitrate was compared to the peripheral arterial nitrate levels of ten healthy infants. The mean pulmonary artery (PA) pressure and pulmonary vascular resistance (Rp) were significantly higher in the DS group than ND patients, and the pulmonary blood flow (Qp) in ND patients was higher than DS patients. There were no differences between the two study groups in regard to plasma ET-1 and nitrate levels obtained from matched sampling sites. The plasma ET-1 and nitrate levels were significantly higher in both study groups compared to the control subjects. The plasma ET-1 and nitrate levels in DS patients with PH were not different when compared to those of ND patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18682983     DOI: 10.1007/s00431-008-0803-1

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  21 in total

1.  Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation.

Authors:  M Yoshibayashi; K Nishioka; K Nakao; Y Saito; M Matsumura; T Ueda; S Temma; G Shirakami; H Imura; H Mikawa
Journal:  Circulation       Date:  1991-12       Impact factor: 29.690

2.  Altered regulation of the ET-1 cascade in lambs with increased pulmonary blood flow and pulmonary hypertension.

Authors:  S M Black; J M Bekker; M J Johengen; A J Parry; S J Soifer; J R Fineman
Journal:  Pediatr Res       Date:  2000-01       Impact factor: 3.756

3.  Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells.

Authors:  I Komuro; H Kurihara; T Sugiyama; M Yoshizumi; F Takaku; Y Yazaki
Journal:  FEBS Lett       Date:  1988-10-10       Impact factor: 4.124

4.  Precocity of pulmonary vascular obstruction of Down's syndrome.

Authors:  P Soudon; M Stijns; M Tremouroux-Wattiez; A Vliers
Journal:  Eur J Cardiol       Date:  1975-04

5.  The pulmonary vascular bed in children with Down syndrome.

Authors:  J Chi TPL?Krovetz
Journal:  J Pediatr       Date:  1975-04       Impact factor: 4.406

6.  Plasma nitric oxide products correlate with cardiac index of congenital heart disease.

Authors:  J Takaya; Y Ikemoto; M Teraguchi; S Nogi; Y Kobayashi
Journal:  Pediatr Cardiol       Date:  2000 Jul-Aug       Impact factor: 1.655

7.  Relation of elevated plasma endothelin in congenital heart disease to increased pulmonary blood flow.

Authors:  J A Vincent; R D Ross; J Kassab; J M Hsu; W W Pinsky
Journal:  Am J Cardiol       Date:  1993-05-15       Impact factor: 2.778

8.  Pulmonary vascular disease and operative indications in complete atrioventricular canal defect in early infancy.

Authors:  S Yamaki; H Yasui; H Kado; K Yonenaga; Y Nakamura; T Kikuchi; H Ajiki; M Tsunemoto; H Mohri
Journal:  J Thorac Cardiovasc Surg       Date:  1993-09       Impact factor: 5.209

9.  Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease.

Authors:  I Adatia; S E Barrow; P D Stratton; V M Miall-Allen; J M Ritter; S G Haworth
Journal:  Circulation       Date:  1993-11       Impact factor: 29.690

Review 10.  Intact and altered endothelium in regulation of vasomotion.

Authors:  A Lerman; J C Burnett
Journal:  Circulation       Date:  1992-12       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.